Microbix and Seegene Mexico Collaborate to Enhance HPV Test Accuracy

Microbix Biosystms ( (TSE:MBX) ) has provided an announcement.

Microbix Biosystems Inc. and Seegene Mexico have partnered to enhance the accuracy of HPV tests across Mexico by utilizing Microbix’s quality assessment products with Seegene’s molecular multiplex assays. This collaboration aims to improve public health efforts for cervical cancer surveillance and ensure high international quality standards in clinical labs, with potential expansion into other infectious disease diagnostics.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Spark’s Take on TSE:MBX Stock

According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.

Microbix Biosystems’ overall stock score is primarily influenced by its strong financial performance and stability, despite recent revenue challenges. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. The earnings call reflects both immediate challenges and potential for future growth, balancing the overall outlook.

To see Spark’s full report on TSE:MBX stock, click here.

More about Microbix Biosystms

Microbix Biosystems Inc. is a life sciences company that creates proprietary biological products for human health. With over 120 skilled employees, it generates significant revenue by manufacturing and exporting critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products.

Average Trading Volume: 51,810

Technical Sentiment Signal: Sell

Current Market Cap: C$33.36M

For detailed information about MBX stock, go to TipRanks’ Stock Analysis page.